| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002489027 |
| P356 | DOI | 10.1023/A:1025874502181 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1023/a:1025874502181 |
| P698 | PubMed publication ID | 14598887 |
| P2093 | author name string | Gang Li | |
| Jason A. Bush | |||
| P2860 | cites work | Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability | Q24300451 |
| bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death | Q24312157 | ||
| Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma | Q24540048 | ||
| The Fas signaling pathway: more than a paradigm | Q28201953 | ||
| The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis | Q28213522 | ||
| Death receptors: signaling and modulation | Q28280897 | ||
| Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions | Q28343497 | ||
| Accelerated disappearance of melanocytes in bcl-2-deficient mice | Q28507369 | ||
| The Bcl-2 protein family: arbiters of cell survival | Q29618158 | ||
| Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis | Q30661571 | ||
| Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry | Q31121392 | ||
| Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. | Q48548442 | ||
| bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. | Q50764553 | ||
| Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma. | Q53460657 | ||
| Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance. | Q53999039 | ||
| Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. | Q54013061 | ||
| Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. | Q54013066 | ||
| Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. | Q54795672 | ||
| Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. | Q55473040 | ||
| Bcl-XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy | Q59296605 | ||
| Bcl-2 expression in malignant melanoma and its prognostic significance | Q71475811 | ||
| Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi | Q72574745 | ||
| Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice | Q73035578 | ||
| Telomerase activity and expression of apoptosis and anti-apoptosis regulators in the progression pathway of human melanoma | Q73072082 | ||
| Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components | Q73212480 | ||
| Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2 | Q73615065 | ||
| Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas | Q73733134 | ||
| p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide | Q73877603 | ||
| Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma | Q73926153 | ||
| c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice | Q74093416 | ||
| bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice | Q74165698 | ||
| Quercetin inhibits the invasion and mobility of murine melanoma B16-BL6 cells through inducing apoptosis via decreasing Bcl-2 expression | Q74248845 | ||
| Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response | Q74302883 | ||
| Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death | Q74504191 | ||
| Report on the Eighth World Congress on Cancers of the Skin 18-21 July 2001, Zurich, Switzerland | Q74609837 | ||
| Expression of apoptosis regulators in cutaneous malignant melanoma | Q77151107 | ||
| Expression of oncogenes, tumour suppressor, mismatch repair and apoptosis-related genes in primary and metastatic melanoma cells | Q77193447 | ||
| CREB and its associated proteins act as survival factors for human melanoma cells | Q77229224 | ||
| Update of diagnostic and prognostic markers in cutaneous malignant melanoma | Q78014397 | ||
| Bcl2 and Bax expression in naevi and melanomas and their relation to ploidy status and proliferation | Q78018207 | ||
| Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma | Q78031920 | ||
| Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma | Q78567057 | ||
| Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome | Q78696414 | ||
| Melanocyte biology and its implications for the clinician | Q33598319 | ||
| Uveal melanoma: natural history and treatment options for metastatic disease. | Q33830987 | ||
| Skin cancer and solar UV radiation | Q33859295 | ||
| The histogenesis and biologic behavior of primary human malignant melanomas of the skin | Q34054176 | ||
| Epidemiology of melanoma | Q34067597 | ||
| The genetics of cutaneous melanoma | Q34163884 | ||
| Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies | Q34167711 | ||
| Breaking the mitochondrial barrier | Q34286380 | ||
| Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model | Q34329975 | ||
| Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system | Q34366036 | ||
| The machinery of programmed cell death. | Q34466450 | ||
| Ki67 protein: the immaculate deception? | Q34570709 | ||
| The new melanoma staging system | Q34573027 | ||
| Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment | Q34773975 | ||
| Bcl-2 family of proteins: life-or-death switch in mitochondria | Q34990149 | ||
| Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. | Q35774469 | ||
| Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner | Q39459265 | ||
| Chemosensitisation of malignant melanoma by BCL2 antisense therapy | Q40611574 | ||
| The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells | Q40659392 | ||
| Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice | Q40672841 | ||
| Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends | Q40704208 | ||
| Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity | Q40707392 | ||
| Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages | Q40747511 | ||
| Current treatment options for malignant melanoma | Q40856163 | ||
| Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma | Q40912648 | ||
| Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines | Q41025453 | ||
| Anti-cell death activity promotes pulmonary metastasis of melanoma cells | Q41104241 | ||
| Malignant melanoma: the role of radiation therapy revisited | Q41274832 | ||
| Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival | Q41671359 | ||
| Bcl-2 expression in human melanocytes and melanocytic tumors | Q41867381 | ||
| Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. | Q41901851 | ||
| The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. | Q41989625 | ||
| Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. | Q42031677 | ||
| Keratinocytes regulate melanocyte number in human fetal and neonatal skin equivalents | Q42473302 | ||
| bcl-2 Expression in Primary Malignancies of the Skin | Q42481272 | ||
| bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation | Q42481277 | ||
| bcl-2 protein expression in melanocytic neoplasms of the skin. | Q42486565 | ||
| A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. | Q42489870 | ||
| Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects | Q42817082 | ||
| Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. | Q43548174 | ||
| Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells | Q43700550 | ||
| A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. | Q44052698 | ||
| Transducible peptide therapy for uveal melanoma and retinoblastoma | Q44169189 | ||
| Roles of activated Src and Stat3 signaling in melanoma tumor cell growth | Q44172485 | ||
| A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity | Q45888474 | ||
| Bax-induction gene therapy of pancreatic cancer. | Q45888545 | ||
| Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma | Q47719197 | ||
| What's new in the treatment of cutaneous melanoma? | Q47821348 | ||
| Prognostic value of biomarkers in malignant melanoma | Q47846540 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncology | Q162555 |
| P304 | page(s) | 531-539 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Clinical & Experimental Metastasis | Q13470030 |
| P1476 | title | The role of Bcl-2 family members in the progression of cutaneous melanoma | |
| P478 | volume | 20 |
| Q37815139 | A new era: melanoma genetics and therapeutics |
| Q42730827 | Bioinformatic prediction of ultraviolet light mutagenesis sensitivity of human genes and a method for genetically engineering UVB resistance |
| Q42620190 | Changes of PI3K/AKT/BCL2 signaling proteins in congenital Giant Nevi: melanocytes contribute to their increased survival and integrity. |
| Q40005203 | Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells |
| Q39027219 | Dioscin-induced apoptosis of human LNCaP prostate carcinoma cells through activation of caspase-3 and modulation of Bcl-2 protein family |
| Q28279156 | EDAG regulates the proliferation and differentiation of hematopoietic cells and resists cell apoptosis through the activation of nuclear factor-kappa B |
| Q41941878 | Expression and function of bcl-2 proteins in melanoma |
| Q33572578 | Expression of Bcl-2, Melan A and HMB-45 in Dysplastic Nevi |
| Q34123184 | Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1 |
| Q39905603 | Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide |
| Q30429380 | Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma |
| Q42777861 | Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model. |
| Q36742015 | Melanoma biology and new targeted therapy |
| Q35125118 | Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells |
| Q26822633 | MicroRNAs: molecular features and role in cancer |
| Q39619870 | Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction |
| Q36953849 | Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. |
| Q34986178 | Novel targeted therapies for the treatment of metastatic melanoma |
| Q33403800 | Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial |
| Q36839762 | Oblimersen in the treatment of metastatic melanoma |
| Q37330218 | Peptides and peptide mimics as modulators of apoptotic pathways. |
| Q28534817 | Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells |
| Q33494047 | RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway |
| Q37355450 | Reduced Apaf-1 expression in human cutaneous melanomas |
| Q34146431 | Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. |
| Q51746852 | Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. |
| Q34400199 | The novel tumor suppressor p33ING2 enhances UVB-induced apoptosis in human melanoma cells |
| Q37951743 | Towards new therapeutic approaches for malignant melanoma |
| Q36691820 | Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance |
Search more.